Surfactant use outside the tertiary care centre

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology

Background:

• Respiratory distress syndrome (RDS) is a significant cause of morbidity and mortality in preterm infants.
• Timely intervention is crucial for improving outcomes in premature neonates.

Purpose of the Study:

• To evaluate the benefits of early surfactant administration in preterm infants.
• To assess the impact of surfactant therapy on pulmonary complications and survival rates.

Main Methods:

• Administration of surfactant shortly after birth to intubated preterm infants (<30 weeks gestation).
• Monitoring for potential adverse effects like transient bradycardia or hypoxemia.
• Evaluating reduction in pulmonary air leak, chronic lung disease, and mortality.

Main Results:

• Early surfactant administration significantly decreases pulmonary air leak.
• Reduces the incidence of chronic lung disease and mortality in preterm neonates.
• May cause transient bradycardia or hypoxemia but rapidly improves lung function.

Conclusions:

• Early surfactant therapy is a life-saving intervention for preterm infants with RDS.
• Peripheral hospitals should establish protocols for surfactant administration in collaboration with referral centers.
• Ensuring access to surfactant therapy at peripheral sites can prevent severe neonatal complications.